If the scale has stopped moving on semaglutide, or never really started, you are not alone and you are not failing the medication. Plateaus and slow starts on this class of drug are common, and almost all of them have an explainable cause that a provider can help address.
The point of this article is not to make you feel bad about anything you might be doing wrong. It is to walk through the most common reasons the scale stalls so you can have a more useful conversation at your next visit.
If you feel your treatment isn’t working, speak with your provider before making any changes. Protocol adjustments can often help significantly.
It Is Almost Always Addressable
Before getting into specific causes, hold onto this: weight loss on semaglutide is rarely a linear downward line. The scale moves in waves. Patients who track daily weights often see fluctuations that obscure the longer trend.
Patients who weigh once a week or once every two weeks usually see the trend more clearly, and even those weeks can include stretches of nothing happening on the surface even when fat loss is occurring underneath (water retention, muscle changes, hormonal cycles, and digestive variations all influence the number on the scale day to day).
What that means is that two or three weeks of no scale movement is rarely a “real” plateau. Six to eight weeks without movement, or a clear stop after months of progress, is when it makes sense to dig into causes.
Where You Are in the Dose Titration
Semaglutide for weight management starts at 0.25 mg per week and steps up gradually to a maintenance dose of 2.4 mg over about 17 weeks. The lower doses are designed to introduce the medication slowly so the body has time to adjust to the gastrointestinal effects. The therapeutic effect on appetite and weight builds gradually as the dose climbs.
That schedule has a practical implication. If you are still in your first 8 to 12 weeks at low doses, you may not yet be at a dose that produces noticeable appetite suppression for your body. Some patients respond strongly at 0.5 mg or 1.0 mg. Others need to reach 1.7 mg or 2.4 mg before the effect becomes meaningful. Individual variability is real and expected.
If your provider has held you at a lower dose because of side effects, that is a clinical decision worth revisiting at your next visit. Many patients who initially struggle with side effects can tolerate a slow re-escalation once their body has adjusted, and reaching a more therapeutic dose often unlocks progress.
Your Body Adapts, and That Is Normal
Once you are at a therapeutic dose, the body still has its own physiology to contend with. Metabolic adaptation is well documented in weight loss across every method studied, including bariatric surgery, behavioral interventions, and now incretin-based medications.
As fat stores decrease, the body responds by lowering resting metabolic rate, increasing appetite signals, and conserving energy more efficiently. This is not a flaw in your willpower; it is your body trying to defend its prior weight set point.
The good news is that the STEP 4 trial published in JAMA showed that patients who continued weekly semaglutide kept losing weight gradually, with the trend reaching its plateau around week 60 to 68 and total reduction reaching about 17.4% over the trial.
Patients who stopped treatment regained weight. The medication is doing real work in keeping appetite signals quieter than they would otherwise be, and that work continues even when the rate of loss slows.
A plateau after months of progress is often the body recalibrating. A provider may recommend a dose adjustment, a check on protocol consistency, or in some cases the addition of complementary therapies that support metabolic function. Some patients explore NAD+ as part of a broader metabolic support strategy alongside their GLP-1 medication, particularly when energy and overall metabolic resilience feel diminished.
Diet Creep Is Real, and Not a Moral Failing
This is the cause patients are most reluctant to consider, and the one most worth approaching without judgment. Caloric intake creeps up over time on most weight loss approaches, often without the patient noticing. Semaglutide reduces appetite, but it does not eliminate appetite, and as side effects fade and the body adapts, eating patterns can drift.
A few extra bites here, a return to eating out more often, larger portions of items that feel “safe” because the medication used to help control them.
The fix is not a stricter diet or self-flagellation. A short food log over a week or two often makes patterns visible. Many patients find their providers can help them recalibrate based on what is actually happening, with no shame attached.
Timing, Consistency, and Practical Variables
Some plateaus come from variables that have nothing to do with willpower. Inconsistent injection timing (skipping a week or pushing the dose later) reduces blood levels of the medication and the corresponding appetite effect.
Storage issues that affect potency are uncommon but possible. Switching brands or sources mid-protocol can change actual delivered dose. Hydration affects how the medication is absorbed and how the body responds.
The practical version of this is simple. Same day each week, consistent storage, no skipped doses unless instructed by a provider. If your routine has slipped (which happens to virtually everyone over months of treatment), a reset on consistency is sometimes enough by itself to break a plateau.
Underlying Conditions Worth Ruling Out
Not every plateau is about medication or your habits. A handful of underlying conditions can blunt response or cause weight retention even when everything else looks right.
Thyroid function is the first one to consider. Untreated or undertreated hypothyroidism makes weight loss substantially harder regardless of medication. A simple TSH and free T4 panel rules it in or out.
Insulin resistance and metabolic syndrome can also blunt the effect of GLP-1 medications, and some patients benefit from a complementary approach to insulin sensitivity. Polycystic ovary syndrome, sleep apnea, certain medications (some antidepressants, beta-blockers, corticosteroids), and chronic stress with elevated cortisol can all contribute.
For some patients, a more comprehensive peptide therapy approach to overall health optimization addresses underlying issues that GLP-1 medications alone cannot.
In other cases, an adjunctive peptide like sermorelin can support the body composition side of weight loss by helping preserve lean mass during caloric restriction. These are individualized decisions that come out of a real conversation with a provider who has reviewed your full picture.
What Not to Do
A few things to avoid if the scale has stalled. Do not stop the medication abruptly. The data is consistent that stopping leads to weight regain, often quickly. Do not double up doses to “catch up” or push past a plateau on your own. Do not assume the medication is “broken” or “stopped working”; that framing is rarely accurate and tends to lead to decisions that make things worse.
Almost always, a plateau is a signal that something in the protocol, the dose, the lifestyle, or the underlying physiology deserves a fresh look. That look is what a provider visit is for.
Bring This to Your Next Visit
A telehealth follow-up is the most direct path to figuring out what is going on. Your provider can review where you are in the dose schedule, screen for underlying issues, talk through any lifestyle or timing factors, and discuss whether a protocol adjustment makes sense. In a single visit, most patients can identify the cause and leave with a concrete plan. Schedule an appointment today.
If your weight loss has stalled, please talk to your provider before stopping or changing your medication. Plateaus are addressable, but the right response depends on your individual situation. This article is for informational purposes only and does not constitute medical advice.